



INVITRO ANTIOXIDANT, ANTI-INFLAMMATORY, INOVO ANTI-ANGIOGENIC ACTIVITIES AND VIRTUAL SCREENING OF PHYTO CONSTITUENTS OF *CHROMOLENA ODORATA*

Zaver Somani, Rituparna Bhattacharjee, Medha Chodankar and *Abhilash N.

Department of Biochemistry, Garden City College, 16th KM, Old Madras Road, Bangalore – 560049, India

ARTICLE INFO

Article History:

Received 09th May, 2014
Received in revised form
25th June, 2014
Accepted 20th July, 2014
Published online 06th August, 2014

Key words:

Invitro Antioxidant, Anti-Inflammatory,
inovo Anti-angiogenic, Virtual screening,
Chromolena Odorata.

ABSTRACT

Chromolena odorata roots are used by traditional healers in Western Ghats for treating inflammation and tumor suppression. Hence the study tries to validate the use, by invitro antioxidant, anti-inflammatory and *inovo* anti-angiogenic activities. Virtual screening of active constituents of *C.odorata* was done using admet SAR an online web tool followed by molecular docking using autodock. Plant extract had a total phenol content of 30mg/g GAE. In comparison to the standard Ascorbic acid plant extract exhibited significant antioxidant activity by scavenging DPPH (IC₅₀ 104µg) and ABTS ions (IC₅₀ 84µg), reducing Ferric ions (IC₅₀ 50µg) and a Total Antioxidant Capacity of 27.5 mg/g Ascorbic Acid Equivalent. Percentage protection of HRBC by 300mg of plant extract was equivalent to that of 200mg of standard Diclofenec indicating anti-inflammatory activity with an IC₅₀ value of 70µg. In *inovo* anti-angiogenic assay 500mg of extract disrupted the process of angiogenesis. Virtual screening highlighted the possibility of Chalcone, Kaempferide, Tamarixetin and Eupatilin becoming leads in future anti-inflammatory and anti angiogenic drugs.

Copyright © 2014 Zaver Somani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Oxygen has double-edged properties, being essential for life; it can also aggravate the damage within the cell by oxidative events (Shinde *et al.*, 2006). Free radicals generation through both aerobic and anaerobic process leads to the various health problems including cancer, aging, heart diseases, gastric problems etc. At molecular level these free radicals are important mediators of damage to cell structures, nucleic acids, lipids and proteins resulting in inflammation and oncogenesis. The stimulated polynuclear cells at the site of inflammation are capable of producing reactive oxygen species in turn causes tissue damage and could be the reason for developing a chronic process. In this context, the use of medicinal plants with anti-inflammatory and anti-oxidant activity is a classic remedy for preventing and treating inflammations so that they do not become chronic (Ríos *et al.*, 2000, Schinella *et al.*, 2002). During cancer progression, the newly formed tumor-associated blood vessels serve first as feeding/nurturing tubes for a growing tumor and next, as conduits for dissemination of tumor cells that escaped from an established primary tumor. Therefore, control of tumor angiogenesis has become a central issue in the fight against cancer progression since anticancer therapy could be ineffective once tumor cells reach favored secondary organs and generate metastatic foci (Elena *et al.*, 2008).

Traditional healers of Western Ghats seem to have inherited expertise in the usage of medicinal herbs. Precedents showed that herbal formulations used by the traditional healers of Shimoga District Karnataka have immense anti-cancer potential (self communication). Researchers have observed a correlation between anti-oxidant, anti-inflammatory and apoptotic activities in the plant extracts (Ramchoun *et al.*, 2012). With this perspective, the study aims to validate the use of invasive weed *Chromolena odorata* roots by traditional healers in Western Ghats for treating inflammation and tumor suppression.

MATERIALS AND METHODS

Plant Collection and Extraction

The plant and its roots were collected from the location 77.70775°E and 13.02558°N, Karnataka State, India. The plant herbarium was prepared and it was authenticated as *Chromolena odorata* (L.) King & Robinson belonging to the family Asteraceae (Reference No. RRCBI-13668) by Dr.Shiddamallayya N, National Ayurvedic Dietetics Institute, Bangalore. The roots were shade dried, powdered mechanically and stored. About 100g of the powdered material was defatted with petroleum ether and extracted with methanol by soxhlation. The solvent was dried at low temperature. The yield was 15.7 % w/w.

*Corresponding author: **Abhilash, N.**
Department of Biochemistry, Garden City College, 16th KM, Old Madras Road, Bangalore – 560049, India.

Phytochemical Screening

Qualitative estimations for Alkaloids, Flavonoids, Glycosides, Steroids, Cardiac glycosides, Saponins, Resins, Phenols, Tanins, Terpenoids, Quinones, Oxalates, Lignin and Anthraquinones were done as described in Harbone (1973), Trease and Evans (1989) and Sofowora (1993).

Determination of Total Phenol by Folin-Ciocalteu Assay

The total phenolic content of crude methanolic extract was determined by the Folin-Ciocalteu method (Singleton *et al.*, 1974). 1 ml of extract of various concentrations was added to 5 ml of 1:10 diluted FC reagent followed by 4 ml of 1 M Sodium carbonate solution. After 30 minutes of incubation in dark at room temperature, the absorbance was measured at 750 nm using UV-visible spectrophotometer. A calibration curve was constructed using different concentrations of standard Gallic acid. All readings were performed in triplicates and the level of Total Phenol in the extract was calculated from the standard calibration curve. Results were expressed in gallic acid equivalents (mg GAE/g).

Total Antioxidant Assay (Phosphomolybdenum)

0.3 ml of various concentration of plant extract (100 – 500 µg) was added to 3 mL of reagent mixture (0.6 M sulphuric acid, 28 mM sodium phosphate and 4 mM ammonium molybdate) followed by incubation at 95°C for 60 min. After cooling absorption of reaction mixture was measured at 695 nm and the antioxidant activity was expressed as the number of gram equivalents of ascorbic acid (El-Sayed *et al.*, 2012).

Evaluation of DPPH free radical scavenging activity

The free radical scavenging activity of extract was studied by DPPH (2, 2-diphenyl-1-picrylhydrazyl) assay (MS Blois, 1958). 2 ml of DPPH (100 µM) was mixed with various dilution ranging from 20µg to 100µg of extract. After 10 minutes of incubation in dark, the absorbance was measured at 517 nm. All readings were performed in triplicates and the free radical scavenging activity was calculated from equation 1. The concentrations of plant extract and Rutin standard was plotted in X-axis against respective percentage inhibition in Y-axis and their IC₅₀ values were calculated by extrapolating the graph.

$$\text{Equation 1: \% Inhibition} = \frac{(A^* - A) \times 100}{A^*}$$

A* is the absorbance of reagent blank and A is the absorbance of the test sample.

ABTS radical cation decolorization assay

To generate ABTS (2,2'-azino-bis, 3-ethylbenzothiazoline-6-sulphonic acid) radical cation, 50 ml of 2 mM ABTS and 0.3 mL of 17 mM potassium persulfate were mixed together and incubated in the dark for 12-16 h to develop prussian blue colored ABTS⁺ solution which has an absorption maxima at 734 nm (Roberta *et al.*, 1999). To determine scavenging activity of extracts, 400 µl of plant extracts of different

concentrations (20 – 100 µg) were added to 320 µl of ABTS⁺ solution. The absorbance was measured at 734 nm after 10 minutes incubation at room temperature. All readings were performed in triplicates and the free radical scavenging activity was calculated from equation 1. The percentage inhibition of plant extract and Rutin standard was plotted against respective concentrations used and their IC₅₀ values were calculated by extrapolating the graph.

Ferric Reducing Antioxidant Power

Plant extract with varying concentrations ranging in between 100 - 200 µg was made to react with 2.5 ml of 1% potassium ferricyanide. The mixture was incubated in a water bath for 20min at 50°C. The resulting solution was cooled rapidly and 2.5ml of 10% trichloroacetic acid was added followed by centrifugation at 3000rpm for 10min. 5ml of supernatant was mixed with 5ml of distilled water and 1ml of 1% ferric chloride. After 10min absorbance was measured at 700nm (Oyaizu, 1986).

$$\text{Reducing Power} = \frac{\text{Absorbance test} - \text{Absorbance blank}}{\text{Absorbance blank}} \times 100$$

Invitro Anti-Inflammatory Activity

The Human Red Blood Cell (HRBC) membrane stabilization method Fresh whole human blood (5 mL) was collected and transferred to the centrifuged tubes containing EDTA to prevent clotting. The tubes were centrifuged at 3000 rpm for 10 min and were washed three times with equal volume of normal saline. The volume of the blood was measured and reconstituted as 10% v/v suspension with normal saline. The reaction mixture consists of 1.0 mL of test sample of different concentrations (50µg – 400 µg) in normal saline and 0.5 mL of 10% HRBC suspension, 1 ml of 0.2 M phosphate buffer, 1 ml hyposaline were incubated at 37^o C for 30 min and centrifuged at 3,000 rpm for 20 min and the hemoglobin content of the supernatant solution was estimated spectrophotometrically at 560 nm. Diclofenac was used as standard and a control was prepared without extracts. The percentage of HRBC hemolysis and membrane stabilization or protection was calculated by using the following formula (Muruges *et al.*, 1981).

$$\% \text{ Hemolysis} = \frac{\text{Optical density of Test sample}}{\text{Optical density of Control}} \times 100$$

$$\% \text{ Protection} = 100 - \frac{\text{Optical density of Test sample}}{\text{Optical density of Control}} \times 100$$

Anti-Angiogenesis Assay Using Chick Chorioallantoic Membrane

Fertilized hens eggs were procured from Indian Veterinary Research Institute (IVRI) (Bill No-28384), Bangalore, and surface sterilized using 70% alcohol. The eggs were incubated in fan assisted humidified incubator at 35-37^oC. On the 4th day in the laminar flow cabinet, the eggs were wiped with 70% alcohol and shell was cracked out into thin film of the hammock, Egg preparation was covered with sterile glass plate and returned to the incubator. On 5th day the plant extract

100µg, 250µg and 500µg was loaded on the filter paper disc, placed over the blood vessel and eggs were returned to the incubator. Results were observed next day (Domenico Ribatti. 2010).

Virtual Screening of phyto constituents of *C.odorata*.

Ligand preparation

3D structures of active constituents present in *C.odorata* (Phan et al., 2001) viz. 2',4'-Dihydroxy-2,3',6'-trimethoxychalcone (CID 21636239), 4',5,6,7-tetramethoxyflavone (CID 96118), 4-coumaric acid (CID 637542), 9-tigloylretronecine (CID 5352410), 4-hydroxybenzoic acid (CID 135), 7-Angeloylretronecine (CID 5352406), Intermedine N-Oxide (CID 340066), beta-MSH (CID 114843), Rinderine 1-acetate (CID 185847), Eupatilin (CID 5273755), Ferulic acid (CID 445858), Kaempferide (CID 5281666), Protocatechuic acid (CID 72), Sinensetin (CID 145659), Tamarixetin (CID 5281699) and Vanillic Acid (CID 8468) were downloaded from Pubchem. By using JSDraw V1.3.2 inbuilt in admetSAR all the compound's smiles formats were retrieved and used for virtual screening.

ADMET Screening

Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties of drug candidates or environmental chemicals play a key role in drug discovery and environmental hazard assessment. The ADMET structure-activity relationship server, entitled admetSAR, is a comprehensive knowledge and tool for predicting ADMET properties of drug candidates and environmental chemicals. In this server, over 200000 ADMET annotated data points for about 96 thousands of unique compounds have been manually curated from large literatures. The admetSAR server provides a user-friendly interface to easily search a chemical profiles, by CASRN, common name and similarity search. In addition, 30 high predictive QSAR models were implemented in admetSAR for new chemical ADMET properties in silico filtering. admetSAR helps in Optimizing ADMET profiles of Hits or Leads in drug discovery and predicting QSAR-based ADMET properties, toxicity properties and in Environmental Hazard Assessment (Feixiong et al., 2012). Only the compounds which had properties viz., negative blood brain barrier, positive Human Intestinal Absorption, non-carcinogenic, non-toxic and non-substrate to metabolic enzymes were selected for molecular docking studies.

Anti-Inflammatory and Anti-Angiogenic Drug Targets

Nuclear Factor kappa B Receptor

NF-kB regulates many genes involved in the promotion of cancer i.e. clonal expansion, growth, diversification, angiogenesis, adhesion, extravasations, degradation of extracellular matrix and also in constitutive activation. The most direct strategy for blocking activation of NF-kB is to block its DNA binding activity (Garg et al., 2002). Hence Structure of the NF-kappa B p50 homodimer, PDB id: 1SVC

(Muller et al., 1995) was downloaded from Protein Data Bank and processed for docking studies.

Tyrosine kinase Receptor

Tyrosine kinases are important cellular signaling proteins that have a variety of biological activities including cell proliferation and migration. Multiple kinases are involved in angiogenesis, including receptor tyrosine kinases such as the vascular endothelial growth factor receptor. Inhibition of angiogenic tyrosine kinases has been developed as a systemic treatment strategy for cancer (Kristy et al., 2010). Crystal structure of c-Kit receptor protein-tyrosine kinase in complex with Imatinib/Gleevec, PDB Id: 1T46 (Clifford et al., 2004) was downloaded from Protein Data Bank and processed for docking studies.

Human Vascular Endothelial Growth Factor-B

Pathological angiogenesis has a pivotal role in sustaining tumor growth and chronic inflammation. Vascular endothelial growth factor-b (VEGF-B) is a member of the VEGF family of growth factors that regulate blood vessel and lymphatic angiogenesis. Crystal structure of human vascular endothelial growth factor-b, PDB id: 2C7W (Iyer et al., 2006) was downloaded from protein data bank and processed for docking studies.

Molecular docking using Autodock

By using Dock Prep function in UCSF Chimera software (Pettersen et al., 2004) all the PDB files were processed for docking simulation. The Graphical User Interface program Auto-Dock Tools was used for docking studies (Michel et al., 1999). Polar hydrogens were added followed by computing Gasteiger Charges and non polar hydrogen's were merged into the receptor PDB file. The grid box size was set at 62, 62 and 62 Å (x, y, and z) to include all the amino acid residues that are present in the active site of rigid macromolecules which was identified by inbuilt program Auto ligand. Auto Grid 4.2 Program was used to produce grid maps. The spacing between grid points was 0.375 angstroms. The Lamarckian Genetic Algorithm (LGA) was chosen search for the best conformers. During the docking process, a maximum of 10 conformers was considered. The population size was set to 150 and the individuals were initialized randomly. Maximum number of energy evaluation was set to 250000, maximum number of generations 27000, maximum number of top individual that automatically survived set to 1, mutation rate of 0.02, crossover rate of 0.8, Step sizes were 0.2 Å for translations, 50.0° for quaternion and 50.0° for torsions. Cluster tolerance 2.0Å°, external grid energy 1000.0, max initial energy 0.0, max number of retries 10000 and 10 LGA runs were performed. Auto dock results were analyzed to study the interactions and the binding energy of the docked structure.

RESULTS AND DISCUSSION

Preliminary Screening

The phytochemical screening of the plants studied showed the presence of Alkaloids, Flavonoids, Terpenoids, Phenols,

Tanins, Saponins, cardiac glycosides, Steroids and Glycosides; absence of anthraquinones, lignin, oxalate, quinines and Resins.

Antioxidant Activity

In the present investigation, it was found that methanolic extract of *C.odorata* had total phenolic content 30 mg/g GAE exerting antioxidant effect as free radical scavengers. Compared to the standard Ascorbic acid, methanolic extract exhibited good IC₅₀ values (Table 1) at 104µg/ml in DPPH free radical scavenging assay, 84µg/ml in ABTS radical cation decolorization assay, 50 µg/ml in FRAP assay and mg/g of Ascorbic acid equivalent in Phosphomolybdenum assay.

Table 1. Anti oxidant activity of methanolic root extract of *C. odorata* and Ascorbic acid

| Assay | IC ₅₀ values of <i>C.odorata</i> | IC ₅₀ values of Ascorbic acid |
|----------------------------|---|--|
| DPPH Assay | 104 µg/ml | 98 µg/ml |
| ABTS Assay | 84µg/ml | 66 µg/ml |
| FRAP Assay | 50 µg/ml | 60 µg/ml |
| Total Phenol Content | 30 mg/g Gallic Acid Equivalents | |
| Total Antioxidant Activity | 27.5 mg/g Ascorbic Acid Equivalent | |

In vitro Anti-Inflammatory Activity

The plant extract showed significant anti-inflammatory activity by protecting HRBC in hypotonic solution (Table 2). Standard diclofenac results 64.04% and 73.03% at 100 and 200 µg were comparable with that of 200 and 300 µg of plant extract. 70 µg/ml and 40 µg/ml were the IC₅₀ values of plant extract and standard Diclofenec respectively. The plant extract exhibited membrane stabilization effect by inhibiting hypotonicity induced lyses of RBC membrane. The RBC membrane is analogous to the lysosomal membrane and its stabilization implies that the extract may as well stabilize lysosomal membranes. Stabilization of lysosomal membrane plays an important role in limiting the inflammatory response by preventing the release of lysosomal constituents of activated neutrophil such as bactericidal enzymes and proteases, which cause further tissue inflammation and damage upon extra cellular release (Rajendran *et al.*, 2008).

Table 2. % of Hemolysis and Protection of Diclofenec and methanolic extract of *C. odorata*

| Conc of in µg/ml | % of Hemolysis of Extract | % Protection of Extract |
|------------------|---------------------------|-------------------------|
| 100 | 46.06 | 53.9 |
| 200 | 33.71 | 66.3 |
| 300 | 25.80 | 74.2 |
| 400 | 20.22 | 79.7 |

Inovo anti-angiogenic activity

As plausible in the Fig. 1. 500µg of plant extract disrupted the process of angiogenesis in CAM assay. Angiogenesis is necessary for tumor growth and distribution of tumor cells. Inhibiting angiogenesis can be helpful in arresting tumor progression. Sorafenib (NEXAVAR) is a multi targeted inhibitor of Vascular Endothelial Growth Factor and RAF

kinase that has been approved in the USA and European Union (Hood *et al.*, 2002).



Figure 1. 500µg of extract disrupting the process of angiogenesis

Virtual Screening of phyto constituents on *C.odorata*

Among the phyto constituents screened only Chalcone, Kaempferide, Tamarixetin and Eupatilin were qualified to be future anti-inflammatory and anti angiogenic drugs. The qualified compounds were unable to cross blood brain barrier, positive to human intestinal absorption, Non-Substrates for metabolic enzymes (Cyp450 2C9, CYP450 2D6, CYP450 3A4) non carcinogenic and non mutagenic (Table 3). In Molecular docking studies, their low binding energy, total internal energy, inter molecular energy and the number of hydrogen bonds formed indicated their effectiveness in binding anti-inflammatory and anti angiogenic drug target protein (Table 3).




Figure 2. Kaempferide bound in the active site of Receptor Tyrosine Kinase

Plant derived medicines are based upon the premise that they contain natural substances that can promote health and alleviate illness, also the chemical constituents present in the herbal medicine or plant are a part of the physiological functions of living flora and hence they are believed to have better compatibility with human body (Saikat *et al.*, 2010). Present investigation not only validates the use of *C.odorata* by

Table 3. *Insilco* Virtually Screened compounds of *C.odorata*

| MODEL | Chalcone | Kaempferide | Tamarixetin | Eupatilin |
|---|---|---|---|---|
| Blood Brain Barrier | BBB- (0.5255) | BBB- (0.6382) | BBB- (0.6382) | BBB- (0.6825) |
| Human Intestinal Absorption | HIA+ (0.9740) | HIA+ (0.9783) | HIA+ (0.9783) | HIA+ (0.9693) |
| Caco-2 Permeability | Caco2+(0.8599) | Caco2+ (0.8866) | Caco2+(0.8866) | Caco2+ (0.8778) |
| P-glycoprotein Substrate | Substrate (0.5372) | Substrate (0.6384) | Substrate (0.6384) | Substrate (0.6326) |
| P-glycoprotein Inhibitor | Non-Inhibitor (0.6483) Inhibitor (0.5322) | Non-Inhibitor (0.7108) Inhibitor (0.7878) | Non-Inhibitor (0.7108) Inhibitor (0.7878) | Non-Inhibitor (0.5799) Inhibitor (0.8548) |
| Renal Organic Cation Transporter | Non-Inhibitor (0.8919) | Non-Inhibitor (0.8979) | Non-Inhibitor (0.8979) | Non-Inhibitor (0.9180) |
| CYP450 2C9 Substrate | Non-Substrate (0.7241) | Non-Substrate (0.7326) | Non-Substrate (0.7326) | Non-Substrate (0.7599) |
| CYP450 2D6 Substrate | Non-Substrate (0.8483) | Non-Substrate (0.8942) | Non-Substrate (0.8942) | Non-Substrate (0.8614) |
| CYP450 3A4 Substrate | Non-Substrate (0.5000) | Non-Substrate (0.5827) | Non-Substrate (0.5827) | Non-Substrate (0.5000) |
| CYP450 1A2 Inhibitor | Inhibitor (0.8110) | Inhibitor (0.9218) | Inhibitor (0.9218) | Inhibitor (0.8610) |
| CYP450 2C9 Inhibitor | Non-Inhibitor (0.6023) | Inhibitor (0.7560) | Inhibitor (0.7560) | Non-Inhibitor (0.7484) |
| CYP450 2D6 Inhibitor | Non-Inhibitor (0.8297) | Non-Inhibitor (0.6993) | Non-Inhibitor (0.6993) | Non-Inhibitor (0.7310) |
| CYP450 2C19 Inhibitor | Inhibitor (0.6629) | Inhibitor (0.8648) | Inhibitor (0.8648) | Inhibitor (0.5640) |
| CYP450 3A4 Inhibitor | Inhibitor (0.7310) | Inhibitor (0.7348) | Inhibitor (0.7348) | Inhibitor (0.6154) |
| CYP Inhibitory Promiscuity | High CYP Inhibitory Promiscuity (0.7925) | High CYP Inhibitory Promiscuity (0.8546) | High CYP Inhibitory Promiscuity (0.8546) | High CYP Inhibitory Promiscuity (0.8068) |
| Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor (0.9738) Non-Inhibitor (0.8960) | Weak Inhibitor (0.9772) Non Inhibitor (0.8494) | Weak Inhibitor (0.9772) Non Inhibitor (0.8494) | Weak Inhibitor (0.9817) Non Inhibitor (0.8256) |
| AMES Toxicity | Non AMES Toxic (0.9247) | Non AMES toxic (0.9133) | Non AMES toxic (0.9133) | Non AMES toxic (0.9250) |
| Carcinogens | Non Carcinogens (0.8568) | Non-carcinogens (0.9423) | Non-carcinogens (0.9423) | Non-carcinogens (0.9184) |
| Fish Toxicity | High FHMT (0.9551) | High FMHT (0.8612) | High FMHT (0.8612) | High FMHT (0.8520) |
| Tetrahymena Pyriformis Toxicity | High TPT (0.9986) | High TPT (0.9965) | High TPT (0.9965) | High TPT (0.9942) |
| Honey Bee Toxicity | High HBT (0.7937) | High HBT (0.6908) | High HBT (0.6908) | High HBT (0.7528) |
| Biodegradation | Not Ready Biodegradable (0.9290) | Not Ready Biodegradable (0.8952) | Not Ready Biodegradable (0.8952) | Not Ready Biodegradable (0.9651) |
| Acute Oral Toxicity | III (0.6805) | III (0.7362) | III (0.7362) | III (0.5210) |
| Carcinogenicity (Three-class) | Not- required (0.6510) | Not-Required (0.6176) | Not-Required (0.6176) | Not-Required (0.6142) |
| Aqueous solubility | -3.6351 LogS | -3.2219 LogS | -3.2219 LogS | -3.5214 LogS |
| Caco-2 Permeability | 1.1924 LogPapp, cm/s | 0.9162 LogPapp, cm/s | 0.9162 LogPapp, cm/s | 1.1812 LogPapp, cm/s |
| Rat Acute Toxicity | 2.3510 LD50, mol/kg | 2.7192 LD50, mol/kg | 2.7192 LD50, mol/kg | 3.0354 LD50, mol/kg |
| Fish Toxicity | 0.8689 pLC50, mg/L | 0.6628 pLC50, mg/L | 0.6628 pLC50, mg/L | 0.8856 pLC50, mg/L |
| Tetrahymena Pyriformis Toxicity | 2.0641 pIGC50, ug/L | 1.3073 pIGC50, ug/L | 1.3073 pIGC50, ug/L | 1.2355 pIGC50, ug/L |
| Molecular Docking with Tyrosine kinase Receptor: PDB ID - 1T46 | | | | |
| Binding energy | -4.48 | -5.45 | -4.71 | -4.46 |
| Ligand efficiency | -0.19 | -0.25 | -0.2 | -0.18 |
| Inhibition Constant | 516.73µM | 100.77µM | 352.51µM | 538.0µM |
| Intermolecular energy | -6.87 | -6.94 | -6.5 | -6.25 |
| Electrostatic energy | -0.53 | -0.08 | -0.38 | -0.17 |
| Vdw_hb_desolvation energy | -6.34 | -6.87 | -6.12 | -6.08 |
| Total internal energy | -1.04 | -0.65 | -1.22 | -1.39 |
| Torsional energy | 2.39 | 1.49 | 1.79 | 1.79 |
| Unbound energy | -1.04 | -0.65 | -1.22 | -1.39 |
| H-bonds | 02 | 05 | 03 | 01 |
| Molecular Docking with Nuclear Factor kappa B Receptor: PDB ID - 1SVC | | | | |
| Binding energy | -3.82 | -5.86 | -5.78 | -5.96 |
| Ligand efficiency | -0.16 | -0.27 | -0.25 | -0.24 |
| Inhibition Constant | 1.58mM | 50.95µM | 57.89 µM | 42.43µM |
| Intermolecular energy | -6.21 | -7.35 | -7.57 | -7.75 |
| Electrostatic energy | -0.17 | -0.37 | -0.29 | -0.44 |
| Vdw_hb_desolvation energy | -6.04 | -6.97 | -7.28 | -7.32 |
| Total internal energy | -1.28 | -0.65 | -1.25 | -1.41 |
| Torsional energy | 2.39 | 1.49 | 1.79 | 1.79 |
| Unbound energy | -1.28 | -0.65 | -1.25 | -1.41 |
| H-bonds | 01 | 02 | 02 | 02 |
| Molecular Docking with Human Vascular Endothelial Growth Factor-B: PDB ID - 2C7W | | | | |
| Binding energy | -6.18 | -6.23 | -6.3 | -6.99 |
| Ligand efficiency | -0.26 | -0.28 | -0.27 | -0.28 |
| Inhibition Constant | 29.48µM | 27.2 µM | 24.26 µM | 7.51µM |
| Intermolecular energy | -8.57 | -7.72 | -8.09 | -8.78 |
| Electrostatic energy | -0.31 | -0.06 | -0.16 | -0.13 |
| Vdw_hb_desolvation energy | -8.26 | -7.66 | -7.92 | -8.65 |
| Total internal energy | -1.2 | -1.17 | -1.01 | -1.3 |
| Torsional energy | 2.39 | 1.49 | 1.79 | 1.79 |
| Unbound energy | -1.2 | -1.17 | -1.01 | -1.3 |
| H-bonds | 03 | 03 | 03 | 02 |

traditional healers but also highlights the possibility of Chalcone, Kaempferide, Tamarixetin and Eupatilin becoming the leads in treating inflammation and tumor progression. Further methods of isolation, *in vitro* and *in vivo* studies, synergism and pathway analysis will prove beneficial in developing potent anti-cancer drug.

Acknowledgement

The authors are thankful to Dr. Joseph VG, Chairman, Garden City College, Bangalore 560049 for his support, Dr. Nagamani JE, Reader, Garden City College for providing insights for CAM assay and Dr. Rama Rao, National Ayurvedic Dietetics Institute, Bangalore for helping in identification and authenticating the plant.

REFERENCES

- Clifford D Mol, Douglas R Dougan, Thomas R Schneider, Robert J Skene, Michelle L Kraus, Daniel N Scheibe, Gyorgy P Snell, Hua Zou, Bi-Ching Sang and Keith P Wilson 2004. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. *J. Biol. Chem.* 279: 31655-31663.
- Domenico Ribatti 2010. The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. *Pharmaceuticals* 3: 482-513; doi:10.3390/ph3030482.
- Elena I. Deryugina and James P. Quigley 2008. Chapter two: chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules; *methods enzymol* 444: 21-41. Doi: 10.1016/s0076-6879(08)02802-4.
- El-Sayed, S. Abdel-Hameed, Salih A. Bazaid and Mohamed M. Shohayeb 2012. Total Phenolics and Antioxidant Activity of Defatted Fresh Taif Rose, Saudi Arabia. *British Journal of Pharmaceutical Research* 2(3): 129-140.
- Evans W 1989. Trease and Evans, Pharmacognosy. Harcourt Brace & Company.
- Feixiong Cheng, Weihua Li, Yadi Zhou, Jie Shen, Zengrui Wu, Guixia Liu, Philip W. Lee, Yun Tang, 2012. Admetsar: a comprehensive source and free tool for evaluating chemical ADMET properties. *J. Chem. Inf. Model* 52(11): 3099-3105.
- Garg A. and BB Aggarwal 2002. Nuclear transcription factor-kB as a target for cancer drug development. *Leukemia* 16: 1053-1068
- Harborne J 1973. Phytochemical methods London. Chapman and Hall, Ltd.
- Hood JD, Bednarski M, Frausto R, Guccione S, Reissfeld RA, Xiang R 2002. Tumor regression by targeted gene delivery to the neovasculature. *Science* 296:2404-2407.
- Iyer S, Scotney P D, Nash A D, Acharya K R 2006. Crystal structure of human vascular endothelial growth factor-b: identification of amino acids important for receptor binding. *Journal of molecular biology* 359: 76.
- Kristy J Gotink, Henk M W, Verheul 2010. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? *Angiogenesis* 13:1-14, DOI 10.1007/s10456-009-9160-6.
- M S Blois 1958. *Nature* 26: 1199-1200
- M. Oyaizu 1986. *Japan Journal of Nutrition* 44: 307-315.
- Michel F Sanner 1999. Python: A Programming Language for Software Integration and Development. *Journal of Molecular Graphics Mod.* 17: 57-61
- Muller C W, Rey F A, Sodeoka M, Verdine G L, Harrison S C 1995. Structure of the NF-kappa B p50 homodimer bound to DNA. *Nature* 373: 311-317
- Muruges N, Vembar S, Damodaran C 1981. *Toxicology Letters* 8:33.
- Petersen E F, Goddard T D, Huang C C, Couch G S, Greenblatt D M, Meng E C, Ferrin T E 2004. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem.* 25(13):1605-12.
- Rajendran V and Lakshmi KS 2008. *In vitro* and *in vivo* anti-inflammatory activity of leaves of *Symplocos cochinchinensis* (Lour) Moore ssp laurina. *Bangladesh Journal of Pharmacology* 3:121-124.
- Ramchoun M, H Harnafi, C Alem, M Benlyas, L Elrhaffari, S Amrani 2012. Anti-inflammatory, anti-oxidant, and apoptotic activities of four plant species used in folk medicine in the Mediterranean basin. *Pak. J. Pharm. Sci.* 25 (1): 65-72
- Ríos JL, Recio MC, Mániz S and Giner RM 2000. Natural triterpenoids as anti-inflammatory agents. *Studies in Natural Products Chemistry: Bioactive Natural Products* 22: 93-143.
- Roberta Re, Nicoletta Pellegrini, Anna Proteggente, Ananth Pannala, Min Yang and Catherine Rice-Evans 1999. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radical Biology Medicine* 26 (9):1231-1237
- Saikat Sen, Raja Chakraborty, C Sridhar, Y S R Reddy, Biplab De 2010. Free radicals, antioxidants, diseases and phytochemicals: current status and future prospect. *International Journal of Pharmaceutical Sciences Review and Research* 3 (1): 91-100
- Schinella G R, Tournier H A, Prieto J M, Mordujovich de Buschiazzo P, Rios J L 2002. Antioxidant activity of anti-inflammatory plant extracts. *Life Science.* 70: 1023- 1033.
- Shinde V, Dhalwal K, Paradkar AR, Mahadik KR, Kadam SS (2006) Evaluation of *in vitro* antioxidant activity of human placental extract, *Pharmacologyonline* 3: 172-179.
- Singleton, V. L., R Orthofer, R M Lamuela-Raventos 1974. *Methods of Enzymology* 299: 152- 178.
- Sofowora LA 1993. Medicinal plants and traditional medicine in Africa. Spectrum Books Ltd, Ibadan.
- Toan-Thang Phan, Lingzhi Wang, Patrick See, Renee Jacqueline Grayer, Sui-Yung Chan and Seng Teik Lee 2001. Phenolic Compounds of *Chromolaena odorata* Protect Cultured Skin Cells from Oxidative Damage: Implication for Cutaneous Wound Healing. *Biol. Pharm. Bull.* 24(12) 1373-1379
